Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996;122(8):489-94.
doi: 10.1007/BF01187161.

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome

Affiliations

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome

A Reles et al. J Cancer Res Clin Oncol. 1996.

Abstract

Objective: The objective of this study was to analyze the incidence of immunohistochemically detectable p53 protein accumulation in epithelial ovarian carcinomas and to correlate these data with the clinical outcome so as to clarify further the role of p53 mutations in prognosis with these patients.

Methods: Tumor tissues from 179 patients with epithelial ovarian carcinoma were used for immuno-histochemical analysis with monoclonal antibody DO1 and BP 53-12-1 on formalin-fixed, paraffin-embedded tissue.

Results: A total of 78 cases (44%) showed positive nuclear p53 staining. The p53-positive cases were found in all histological types of epithelial ovarian tumors. p53 staining was found in tumors of all stages with a higher percentage of positive cases in stage IV ovarian carcinomas (not significant). Poorly differentiated carcinomas showed a significantly higher percentage of p53 protein expression than did highly differentiated tumors (P = 0.0002). Clinical follow-up of up to 14 years (median 25 months) showed a slightly but not significantly shortened disease-free and overall survival time for patients with p53-positive epithelial ovarian carcinomas.

Conclusions: We conclude from our data that p53 expression in ovarian carcinoma is associated with poor differentiation but not with the disease being in an advanced stage. There was a tendency for shortened disease-free and overall survival for patients with p53-positive tumors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Banks L, Matlashewski G, Crawford L (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529–534 - PubMed
    1. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699–1703 - PubMed
    1. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC (1994) The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246–252 - PubMed
    1. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6:1791–1797 - PubMed
    1. Day TG, Gallager HS, Rutledge FN (1975) Epithelial carcinoma of the ovary: Prognostic importance of histological grade. Natl Cancer Inst Monogr 42:15–18 - PubMed

Substances

LinkOut - more resources